List of Figures:
Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 16
Figure 4. North America Injectable Drugs Market, 2019-2030, $ bn 19
Figure 5. Impact of COVID-19 on Business 23
Figure 6. Primary Drivers and Impact Factors of North America Injectable Drugs Market 25
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 28
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060 28
Figure 9. Primary Restraints and Impact Factors of North America Injectable Drugs Market 30
Figure 10. Investment Opportunity Analysis 34
Figure 11. Porter’s Fiver Forces Analysis of North America Injectable Drugs Market 37
Figure 12. Breakdown of North America Injectable Drugs Market by Molecule Type, 2019-2030, % of Revenue 42
Figure 13. North America Addressable Market Cap in 2021-2030 by Molecule Type, Value ($ bn) and Share (%) 42
Figure 14. North America Injectable Drugs Market by Molecule Type: Small Molecule, 2019-2030, $ bn 43
Figure 15. North America Injectable Drugs Market by Molecule Type: Large Molecule, 2019-2030, $ bn 44
Figure 16. Breakdown of North America Injectable Drugs Market by Drug Class, 2019-2030, % of Sales Revenue 46
Figure 17. North America Addressable Market Cap in 2021-2030 by Drug Class, Value ($ bn) and Share (%) 46
Figure 18. North America Injectable Drugs Market by Drug Class: Monoclonal Antibodies (mAbs), 2019-2030, $ bn 47
Figure 19. North America Injectable Drugs Market by Drug Class: Immunoglobulin, 2019-2030, $ bn 48
Figure 20. North America Injectable Drugs Market by Drug Class: Insulin, 2019-2030, $ bn 49
Figure 21. North America Injectable Drugs Market by Drug Class: Vaccines, 2019-2030, $ bn 50
Figure 22. North America Injectable Drugs Market by Drug Class: Cytokines, 2019-2030, $ bn 51
Figure 23. North America Injectable Drugs Market by Drug Class: Peptide Hormone, 2019-2030, $ bn 52
Figure 24. North America Injectable Drugs Market by Drug Class: Blood Factors, 2019-2030, $ bn 53
Figure 25. North America Injectable Drugs Market by Drug Class: Other Drug Classes, 2019-2030, $ bn 54
Figure 26. Breakdown of North America Injectable Drugs Market by Delivery, 2019-2030, % of Sales Revenue 56
Figure 27. North America Addressable Market Cap in 2021-2030 by Delivery, Value ($ bn) and Share (%) 56
Figure 28. North America Injectable Drugs Market by Delivery: Pre-filled Syringe, 2019-2030, $ bn 57
Figure 29. North America Injectable Drugs Market by Delivery: Infusions, 2019-2030, $ bn 58
Figure 30. North America Injectable Drugs Market by Delivery: Other Deliveries, 2019-2030, $ bn 59
Figure 31. Breakdown of North America Injectable Drugs Market by Application, 2019-2030, % of Revenue 61
Figure 32. North America Addressable Market Cap in 2021-2030 by Application, Value ($ bn) and Share (%) 61
Figure 33. North America Injectable Drugs Market by Application: Oncology, 2019-2030, $ bn 62
Figure 34. North America Injectable Drugs Market by Application: Infectious Diseases, 2019-2030, $ bn 63
Figure 35. North America Injectable Drugs Market by Application: Autoimmune Diseases, 2019-2030, $ bn 64
Figure 36. North America Injectable Drugs Market by Application: Cardiovascular Diseases, 2019-2030, $ bn 65
Figure 37. North America Injectable Drugs Market by Application: Pain, 2019-2030, $ bn 66
Figure 38. North America Injectable Drugs Market by Application: Neurology, 2019-2030, $ bn 67
Figure 39. North America Injectable Drugs Market by Application: Other Applications, 2019-2030, $ bn 68
Figure 40. Breakdown of North America Injectable Drugs Market by Distribution Channel, 2019-2030, % of Revenue 70
Figure 41. North America Addressable Market Cap in 2021-2030 by Distribution Channel, Value ($ bn) and Share (%) 70
Figure 42. North America Injectable Drugs Market by Distribution Channel: Hospital Pharmacy, 2019-2030, $ bn 71
Figure 43. North America Injectable Drugs Market by Distribution Channel: Retail Pharmacy, 2019-2030, $ bn 72
Figure 44. North America Injectable Drugs Market by Distribution Channel: E-Commerce, 2019-2030, $ bn 73
Figure 45. Breakdown of North America Injectable Drugs Market by Country, 2019 and 2030, % of Revenue 75
Figure 46. Contribution to North America 2021-2030 Cumulative Market by Country, Value ($ bn) and Share (%) 76
Figure 47. U.S. Injectable Drugs Market, 2019-2030, $ bn 78
Figure 48. Canada Injectable Drugs Market, 2019-2030, $ bn 80
Figure 49. Injectable Drugs Market in Mexico, 2019-2030, $ bn 82
Figure 50. Growth Stage of North America Injectable Drugs Industry over the Forecast Period 84
North America injectable drugs market is expected to grow by 8.3% annually in the forecast period and reach $372.9 billion by 2030 driven by the increasing prevalence of chronic diseases, rising use of self-administered Injectable formulations, technological advancements in drug development, and growing approvals of new injectable drugs such as COVID-19 vaccines. Highlighted with 23 tables and 50 figures, this 102-page report “North America Injectable Drugs Market 2020-2030 by Molecule Type (Small, Large), Drug Class (mAbs, Immunoglobulin, Insulin, Vaccines, Cytokines, Peptide Hormone, Blood Factors), Delivery (Pre-filled Syringe, Infusions, Others), Application (Oncology, Infectious Diseases, Autoimmune, Cardiovascular), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, E-Commerce), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America injectable drugs market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19). In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America injectable drugs market in every aspect of the classification from perspectives of Molecule Type, Drug Class, Delivery, Application, Distribution Channel, and Country. Based on Molecule Type, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Small Molecule • Large Molecule Based on Drug Class, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Monoclonal Antibodies (mAbs) • Immunoglobulin • Insulin • Vaccines • Cytokines • Peptide Hormone • Blood Factors • Other Drug Classes Based on Delivery, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Pre-filled Syringe • Infusions • Other Deliveries Based on Application, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Oncology • Infectious Diseases • Autoimmune Diseases • Cardiovascular Diseases • Pain • Neurology • Other Applications Based on Distribution Channel, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Hospital Pharmacy • Retail Pharmacy • E-Commerce Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2019-2030. The breakdown of key national markets by Molecule Type, Drug Class, and Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): Amgen Inc. Baxter International Inc. Eli Lilly and Company Gilead Sciences Inc. GlaxoSmithKline PLC Johnson & Johnson Merck & Co. Inc. Moderna, Inc. Novartis AG Novo Nordisk AS Pfizer Inc. Sanofi SA Teva Pharmaceuticals Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More